Systemic pharmacokinetic interaction: aripiprazole + valproic acid

The term "Systemic pharmacokinetic interaction: aripiprazole + valproic acid" refers to the clinical drug-drug interaction (DDI) profile between the atypical antipsychotic aripiprazole and the mood stabilizer valproic acid. This entry does not describe a single biological target, such as a receptor or enzyme, but rather the metabolic relationship between two therapeutic agents when co-administered. Aripiprazole is primarily metabolized by the hepatic cytochrome P450 enzymes CYP3A4 and CYP2D6 (FDA, 2021). Clinical studies have shown that valproate co-administration leads to a modest decrease (approximately 25%) in aripiprazole exposure (Cmax and AUC), which is generally not considered clinically significant enough to warrant dose adjustments (Citrome et al., 2005). Conversely, aripiprazole does not appear to significantly alter the steady-state concentrations of valproate. Monitoring this interaction is essential in psychiatric polypharmacy, particularly for patients with bipolar disorder or schizophrenia, to ensure optimal therapeutic outcomes and to monitor for additive side effects like sedation or tremors.

Other names

Aripiprazole-valproate interactionAripiprazole-valproic acid pharmacokinetic interactionPharmacokinetic interaction of aripiprazole and valproate

Pharmacokinetic interaction involving the modulation of hepatic metabolism via CYP3A4 and CYP2D6 enzymes.